UNSPSC 51343401: Peramivir

This classification denotes an antiviral agent with the molecular formula C15H28N4O4.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QW7Y7ZR15U, chemically known as cyclopentanecarboxylic acid, 3-((1s)-1-(acetylamino)-2-ethylbutyl)-4-((aminoiminomethyl)amino)-2-hydroxy-, (1s,2s,3r,4r)- but generally known as peramivir, which bears US NIH Compound Identifier 151164. European Medicines Agency schedules Peramivir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32136.

Most nations schedule peramivir under HS 29252900 and SITC 51482. As of Q4 2014, PERAMIVIR remains the US FDA Preferred Term for this commodity. Peramivir bears US NLM identifiers UMLS ID C1675326 and NCI Concept Code C81611. SMILES: OC1C(C(/N=C(/N)N)CC1C(=O)O)C(NC(=O)C)C(CC)CC.

UNSPSC 51343401 Peramivir is a Commodity code that nominally covers antiviral medications, but recent state and local procurement activity under this code shows little alignment with peramivir itself. Instead, the opportunities tagged to this code reflect broader pharmaceutical and medical supply procurement — naloxone (opioid-reversal medication), over-the-counter drugs, generic multi-source pharmaceuticals, and emergency medical supplies such as respiratory equipment, cardiac monitoring devices, and bandaging materials. State and local governments are buying these products through fixed-price purchase orders, cooperative purchasing agreements, and formal competitive bidding processes. Issuing bodies include city purchasing departments (Tampa), county health systems (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The code appears to capture pharmaceutical procurement broadly rather than peramivir specifically, suggesting either classification drift or use of this commodity code as a catch-all for antiviral and pharmaceutical product families.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Representative opportunities include Seminole County's IFB for naloxone and drug deactivation systems (1,900 units annually, response due July 26, 2023), the City of Tampa's sealed-bid procurement for medical and first aid supplies for the Fire Department Rescue Division with an estimated contract value of $700,000 and response due March 13, 2026, the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, and the Texas Health and Human Services Commission's RFI regarding direct-to-manufacturer prescription programs (response due April 3, 2026). The Tampa bid includes a 5 percent discount for certified Small Local Business Enterprises, and the MMCAP procurement carries a 3 percent administrative fee structure. None of these opportunities is specifically for peramivir; the code's recent activity reflects pharmaceutical supply and emergency medical goods procurement at the state and local level.